- Home
- APLE vs MRUS Comparison
APLE vs MRUS Comparison
Compare APLE & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLE
- MRUS
- Stock Information
- Founded
- APLE 2007
- MRUS 2003
- Country
- APLE United States
- MRUS Netherlands
- Employees
- APLE N/A
- MRUS N/A
- Industry
- APLE Real Estate Investment Trusts
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- APLE Real Estate
- MRUS Health Care
- Exchange
- APLE Nasdaq
- MRUS Nasdaq
- Market Cap
- APLE 3.3B
- MRUS 2.7B
- IPO Year
- APLE 2015
- MRUS 2016
- Fundamental
- Price
- APLE $11.53
- MRUS $37.86
- Analyst Decision
- APLE Buy
- MRUS Strong Buy
- Analyst Count
- APLE 4
- MRUS 13
- Target Price
- APLE $17.25
- MRUS $86.85
- AVG Volume (30 Days)
- APLE 3.0M
- MRUS 716.9K
- Earning Date
- APLE 05-01-2025
- MRUS 05-07-2025
- Dividend Yield
- APLE 8.64%
- MRUS N/A
- EPS Growth
- APLE 14.64
- MRUS N/A
- EPS
- APLE 0.89
- MRUS N/A
- Revenue
- APLE $1,431,468,000.00
- MRUS $36,133,000.00
- Revenue This Year
- APLE $3.74
- MRUS $37.72
- Revenue Next Year
- APLE $2.90
- MRUS $48.47
- P/E Ratio
- APLE $13.18
- MRUS N/A
- Revenue Growth
- APLE 6.52
- MRUS N/A
- 52 Week Low
- APLE $11.59
- MRUS $37.77
- 52 Week High
- APLE $16.50
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- APLE 16.57
- MRUS 37.61
- Support Level
- APLE $12.65
- MRUS $38.40
- Resistance Level
- APLE $13.06
- MRUS $43.58
- Average True Range (ATR)
- APLE 0.36
- MRUS 2.49
- MACD
- APLE -0.14
- MRUS -0.85
- Stochastic Oscillator
- APLE 4.19
- MRUS 13.16
About APLE Apple Hospitality REIT Inc.
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.